The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on 0800 980 3332
Recruitment to clinical trials may be paused at some hospitals due to the COVID-19 pandemic. Your healthcare team can provide additional details about recruitment to clinical trials in your area.
There are currently 22 open trials
Teclistamab for relapsed and refractory myeloma
This trial is investigating whether a drug called teclistamab is safe and effective for the treatment of relapsed and/or refractory myeloma patients.
Teclistamab is is a new type of immunotherapy called a bispecific antibody. It works by helping your T-cells (a type of immune cells) find and kill myeloma cells.
University College Hospital, London;
The Royal Marsden Hospital, Sutton
Who can enter the study?:
Relapsed and/or refractory myeloma patients who have received at least three lines of treatment including an immunomodulatory drug (e.g. lenalidomide (Revlimid)), a proteasome inhibitor (e.g. bortezomib (Velcade)) and an anti-CD38 monoclonal antibody (e.g. daratumumab (Darzalex)).
Patients will be given teclistamab subcutaneously (injection into the skin).
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
(for Medical Professionals):
A Phase II, open-label clinical trial evaluating the safety and efficacy of teclistamab for relapsed and/or refractory myeloma.
For more information, click here.